Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33RD Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced that the company, along with one of their collaborators, Dr. Sekwon Jang of the Inova Cancer Center, will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.

Following is a list of abstracts that will be presented at the meeting.

Rapid Oral Abstract Presentation Session
Session	Title & Presenter	Day & Time	Location
Rapid Oral Abstracts	Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment Presenter: Sekwon Jang, MD Director, Melanoma and Cutaneous Oncology Therapeutics and Research Inova Melanoma and Skin Cancer Center	November 9: 1:40 pm	204ABC
Scientific Poster Presentations
Poster Number & Session	Title & Presenter	Day & Time	Location
P13 Biomarkers and Immune Monitoring	Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment Presenter: Charles W. Abbott, PhD	November 9: 12:45pm-2:15pm and 6:30pm-8:00pm	Hall E
P151 Cancer Vaccines, Personalized Vaccines and Technologies, Personalized Medicine	Improving neoantigen identification for therapeutic and diagnostic use in immuno-oncology using mass spectrometry and machine learning Presenter: Sean M. Boyle, PhD	November 9: 12:45pm-2:15pm and 6:30pm-8:00pm	Hall E
P78 Biomarkers and Immune Monitoring	More sensitive identification of T-cell receptor beta rearrangements with an augmented transcriptome method Presenter: Eric Levy, PhD	November 10: 12:20pm-1:50pm and 7:00pm-8:30pm	Hall E

Personalis will also be exhibiting during the conference (Booth #617). Representatives will be available to answer questions about the company’s cancer immunogenomics services.

About Personalis, Inc.

Personalis, Inc. is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.